Top Back to top

Outcomes of Allogeneic HCT in patients with Hodgkin Lymphoma in the era of Checkpoint Inhibitors: A joint CIBMTR and EBMT analysis.

Lymphoma Working Party (LWP)
Study number:
2020-R-03
Short title:
Allo HSCT For HL in the era of Checkpoint Inhibitors
Study status:
 
Deadline for data collection:
 
Study design:
 
Primary objective:
 
Key inclusion criteria:
 
Country:
 
Principal investigator:
Miguel-Angel Perales
Principal investigator email:
peralesm@mskcc.org
EBMT Study coordinator:
Hervé Finel
Study coordinator email:
herve.finel@upmc.fr